Ernexa Therapeutics (ERNA) vs NuCana (NCNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NuCana is the larger company by market cap ($4.7 million vs $4.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ERNA | NCNA |
|---|---|---|
| Share price | $2.61 | $1.13 |
| Market cap | $4.25M | $4.70M |
| 1-day change | +9.09% | -0.88% |
| EPS (TTM) | $-13.63 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $6.40 |
| 52-week low | $2.14 | $0.948 |
| Distance from 52-week high | -96.36% | -82.34% |
| Average volume | 472.01K | 123.99K |
| Shares outstanding | 1.63M | 4.16M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ERNA vs NCNA FAQ
Which is bigger, Ernexa Therapeutics or NuCana?
NuCana (NCNA) is larger, with a market capitalization of $4.70M compared with $4.25M for Ernexa Therapeutics (ERNA).
Are Ernexa Therapeutics and NuCana in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.